TABLE 5.
Neutralization of HIV-1JR-CSF by MAbs alone or in combinationa
| Antibody 2b | ID90 of antibody 1 alone or in combination with antibody 2c
|
||
|---|---|---|---|
| IgG1 b12 | 2G12 | 2F5 | |
| None | 25 | 200 | 100 |
| IgG1 b12 (10) | 25 | >50 | |
| 2G12 (50) | 12.5 | 25 | |
| 2F5 (50) | 12.5 | 50 | |
a
Neutralization synergy of antibody combinations for HIV-1JR-CSF was assessed by using an alternative approach to determining synergy in which the neutralization dose-response curve of one MAb (antibody 1) was assessed in the presence or absence of a fixed, weakly neutralizing concentration of a second MAb (antibody 2).
b
The fixed concentration of antibody 2 is indicated in micrograms per milliliter in parenthesis.
c
ID90s are shown in micrograms of antibody 1 per milliliter alone or in combination with a weakly neutralizing concentration of antibody 2. A decrease in the ID90 of antibody 1 indicates synergy.